Test my supply
+4 more ↓
66%
Finnrick rating
#227 of 301 ranked vendors
215 of 302 classifiable tests passed
methodology · Purity focus
Finnrick analysis

LiliPeptide's purity-focused evidence is strongest for GHK-Cu, while Retatrutide and Tirzepatide look lot-dependent rather than steady. The record is large and current but dispersed: TB-500, CJC-1295, Tesamorelin and NAD+ show repeated purity misses, identity failures or major fill outliers, with batch-ID gaps tempering confidence.

methodology →
vendor intelligence report
Vendor Intelligence Report: LiliPeptide

Public records and web artifacts leave the listed U.S. location unsupported and point toward a China/Hong Kong operating stack. The report maps the typo-domain network, PeptSlim/ElitePeptide66 overlap, rotating contact personas and post-payment courier-fee complaints.

27 pages5 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.06
94%
25
2
Tirzepatide
$0.53
80%
40
3
Retatrutide
$0.93
79%
141
4
BPC-157
$0.70
72%
22
5
PT-141
$0.75
65%
9
6
Ipamorelin
$0.95
62%
9
8
Tesamorelin
$2.50
52%
22
9
MOTS-c
$0.80
37%
9
10
CJC-1295
$2.20
25%
5
11
NAD+
$0.02
23%
4
12
TB-500
$1.75
22%
14
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%1 Jun 2026: 66%1 Jun 2026: 66%1 Jun 2026: 66%1 Jun 2026: 66%1 Jun 2026: 66%1 Jun 2026: 66%1 Jun 2026: 66%1 Jun 2026: 66%2 Jun 2026: 66%2 Jun 2026: 66%2 Jun 2026: 66%4 Jun 2026: 66%4 Jun 2026: 66%12 Jun 2026: 66%15 Jun 2026: 66%15 Jun 2026: 66%16 Jun 2026: 66%16 Jun 2026: 66%16 Jun 2026: 66%17 Jun 2026: 66%17 Jun 2026: 66%24 Jun 2026: 66%24 Jun 2026: 66%24 Jun 2026: 66%24 Jun 2026: 67%24 Jun 2026: 67%1 Jul 2026: 67%9 Jul 2026: 66%13 Jul 2026: 67%13 Jul 2026: 66%13 Jul 2026: 66%13 Jul 2026: 67%14 Jul 2026: 66%20 Jul 2026: 66%21 Jul 2026: 66%21 Jul 2026: 66%30 Jul 2026: 66%30 Jul 2026: 66%3 Aug 2026: 66%3 Aug 2026: 66%10 Aug 2026: current 66%66%67%66%Jun 26Aug 26
Test my supply
LiliPeptide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
3 Aug 2026Fail
MOTS-c
lab nameView COA
3 Aug 2026Pass
Retatrutide
lab nameView COA
30 Jul 2026Pass
Tirzepatide
lab nameView COA
30 Jul 2026Pass
Retatrutide
lab nameView COA
21 Jul 2026Pass
Tirzepatide
lab nameView COA
21 Jul 2026Pass
Tirzepatide
lab nameView COA
20 Jul 2026Pass
Retatrutide
lab nameView COA
14 Jul 2026Fail
MOTS-c
lab nameView COA
13 Jul 2026Fail
Tesamorelin
lab nameView COA
13 Jul 2026Pass
Tirzepatide
lab nameView COA
1-10 of 200

About LiliPeptide test results from Finnrick

LiliPeptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 304 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible LiliPeptide peptides in this dataset are BPC-157 (22 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Test my supply